REDUCE Trial: Perineural Dexamethasone on Scalp Nerve Blocks

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04648358
Collaborator
(none)
98
1
2
18.6
5.3

Study Details

Study Description

Brief Summary

Pain is common in the first 2 days after major craniotomy. Inadequate analgesia may lead to an increased risk of postoperative complications. Most pain following craniotomy arises from the pericranial muscles and soft tissues of the scalp. Scalp nerve blocks with local anesthesia seem to provide effective, safe, however transient postoperative analgesia which does not seem to meet the requirements of craniotomy. Currently, peripheral dexamethasone has been observed to significantly prolong the duration of analgesia of nerve blocks (e.g., saphenous nerve block, adductor canal block, thoracic paravertebral block, brachial plexus nerve block). On the contrary, a study reported that perineural dexamethasone did not appear to prolong the analgesic time after supratentorial craniotomy. However, all patients in this study were given 24 mg of oral or intravenous dexamethasone regularly at least 7 days during the perioperative period, which possibly masked the role of single local low doses of perineural dexamethasone. Therefore, the analgesic effect of single dexamethasone for scalp nerve blocks without the backdrop of perioperative glucocorticoid deserves further clarification.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
98 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
REDUCE Trial: The Effects of Perineural Dexamethasone on Scalp Nerve Blocks for Relief of Postcraniotomy Pain
Actual Study Start Date :
Dec 13, 2020
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control group

The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000

Drug: Bupivacaine
The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

Experimental: DEX4mg group

DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.

Drug: Dexamethasone combined with bupivacaine
The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

Outcome Measures

Primary Outcome Measures

  1. The duration of analgesia [Within 48 hours after surgery]

    The time between the performance of the block and the administration of the first press the PCA demand button postoperatively.

Secondary Outcome Measures

  1. Sufentanil consumption [At 4, 12, 24 and 48 hours postoperatively]

    The cumulative amount of sufentanil consumption by PCA

  2. Numeric rating scale (NRS) [At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperatively]

    NRS: 11-point scale in which 0 = no pain to 10 = worst imaginable pain. An NRS score ≥4 will be considered significant or moderate pain. An NRS score ≥7 will be considered severe pain. Meanwhile, the localization of the site of the pain will also be documented.

  3. Glasgow Coma Scale (GCS) [At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperatively]

    A scale for measuring level of consciousness, in which scoring is determined by three factors: amount of eye opening, verbal responsiveness, and motor responsiveness.

  4. Postoperative nausea and vomiting (PONV) [Within 48 hours after surgery]

    Vomiting will be defined as the forceful expulsion of gastric contents, and nausea will be defined as an unpleasant sensation associated with the urge to vomit.

  5. Bradycardia [Within 48 hours after surgery]

    Bradycardia will be defined as HR<60 beats/minute in at least two instances more than 5 minutes apart.

  6. Hypotension [Within 48 hours after surgery]

    Hypotension will be defined as any of the following: systolic BP <90 mm Hg for 5 minutes or a 35% decrease in mean arterial blood pressure.

  7. Emergence delirium [Within 48 hours after surgery]

    Emergence delirium will be assessed by the Sedation Agitation Scale (SAS), a 7-point scale on which a higher score represents greater agitation.

  8. The length of stay (LOS) [About at 2 weeks after surgery]

    The LOS will be defined as the number of nights spent in the hospital after surgery.

  9. Patient satisfaction score (PSS) [At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperatively]

    PSS: 0 for unsatisfactory to 10 for very satisfactory.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • scheduled for elective supratentorial craniotomy under general anesthesia;

  • age 18 to 64 years;

  • an American Society of Anesthesiologists (ASA) physical status of I, II or III;

  • preoperative Glasgow Coma Scale (GCS) score of 15/15.

Exclusion Criteria:
  • History of chronic headache or chronic pain syndrome of any cause, psychiatric disorders, or uncontrolled epilepsy;

  • Inability to understand or use the pain scales before surgery;

  • Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 hours before surgery;

  • Request of oral/intravenous glucocorticoid to decrease cerebral edema within 1 week before surgery;

  • Pregnancy or breastfeeding;

  • Extreme body mass index (BMI) (< 15 or > 35);

  • Participation in another interventional trial that interferes with the intervention or outcome of this trial;

  • Refusal or inability of the patient and/or legal guardian to provide informed consent;

  • Coagulopathy;

  • Infection around the puncture point;

  • History of allergies to any of the study drugs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Tiantan Hospital Beijing Beijing China 100070

Sponsors and Collaborators

  • Beijing Tiantan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fang Luo, Director of Department of Pain Management, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT04648358
Other Study ID Numbers:
  • KY 2018-034-02-9
First Posted:
Dec 1, 2020
Last Update Posted:
Dec 29, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 29, 2020